The Hindu Business Line : Ranbaxy launches urology drug Soliten

Ranbaxy Laboratories today announced the launch of its Soliten brand (Solifenacin) in the Indian market for the management of chronic urological disorders.

The product is being introduced for the first time in India. Soliten will be sold in 5 mg and 10 mg dosage tablets.

Soliten is a formulation for providing relief from chronic problems of overactive bladder.

According to a company release, the product is documented to have fewer side effects and greater effectiveness.

Commenting on the launch, Mr Sanjeev I. Dani, Regional Director (India & Middle East), Ranbaxy, said: "An overactive bladder largely remains untreated due to prevailing low awareness among sufferers.

"The introduction of Soliten will strengthen the options available to urologists in treating the symptoms of this highly uncomfortable and annoying medical condition."

One out of every eleven individuals above 40 is believed to suffer from an overactive bladder.

The problem is equally common among men and women and more dominant among the urban population.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
India on Merck's research radar

APPM to import used machine

Swaraj Mazda for arbitration to solve PTL, Sumitomo legal dispute

Panyam Cements may sell engg division

Silverline finalises one-time settlement

Dollex set to acquire Godavari Manar Sugar

IOC execs to be trained by U21Global

Hansgrohe ties up with Jaquar

Govt unhappy with IOC's non-fuel retailing foray

KCP looks to diversify

Reliance Ind still hopeful of Govt compensation

Dunlop negotiating with Tata Motors for OE tyre supply

Ranbaxy launches urology drug Soliten